Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China. Pfizer has entered into an exclusive global licensing agreement with 3SBio to ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines. 3SBio plans to initiate the first Phase 3 study in China in 2025. Under the terms of the agreement ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech ...